Avalyn Pharma Inc. (NASDAQ:AVLN)
| Market Cap | $1.36B+3.7% |
| Revenue (ttm) | $0 |
| Net Income | -$85.46M |
| EPS | -$1.29 |
| Shares Out | 44.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 499,880 |
| Open | $30.78 |
| Previous Close | $31.62 |
| Day's Range | $28.15 - $31.39 |
| 52-Week Range | $22.24 - $40.17 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $60.00(+96.14%) |
| Earnings Date | Nov 12, 2026 |
About AVLN
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
1 firm rating AVLN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
$AVLN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AVLN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AVLN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AVLN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AVLN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AVLN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AVLN
| VTIVanguard Morningstar Total Stock Market ETF | $15.23M |
| IWMiShares Russell 2000 ETF | $14.93M |
| VXFVanguard Extended Market ETF | $5.68M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $5.01M |
| IWOiShares Russell 2000 Growth ETF | $3.70M |
| VTWOVanguard Russell 2000 ETF | $3.00M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AVLN’s recent data — informational, not investment advice